Rhythm Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Rhythm Pharmaceuticals has a total shareholder equity of $133.6M and total debt of $109.8M, which brings its debt-to-equity ratio to 82.2%. Its total assets and total liabilities are $372.7M and $239.2M respectively.
Key information
82.19%
Debt to equity ratio
US$109.79m
Debt
| Interest coverage ratio | n/a |
| Cash | US$291.03m |
| Equity | US$133.58m |
| Total liabilities | US$239.15m |
| Total assets | US$372.73m |
Recent financial health updates
Recent updates
Rhythm Pharmaceuticals: Exciting Times With sNDA PDUFA Date
Sep 25Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%
Jul 10
Rhythm Pharmaceuticals (NASDAQ:RYTM) Has Debt But No Earnings; Should You Worry?
Jun 25
Label Expansion And Global Healthcare Will Widen Future Market Opportunities
Label expansion and global commercialization of IMCIVREE are set to drive substantial revenue growth and broaden market reach.Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up
May 04Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder
Apr 08Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven
Feb 25Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 19Rhythm Pharmaceuticals: A Key Year Ahead
Dec 06Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
Sep 22Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)
Aug 29Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Jun 12Rhythm Pharmaceuticals: Action Too Specific
Feb 23Financial Position Analysis
Short Term Liabilities: RYTM's short term assets ($360.7M) exceed its short term liabilities ($129.5M).
Long Term Liabilities: RYTM's short term assets ($360.7M) exceed its long term liabilities ($109.7M).
Debt to Equity History and Analysis
Debt Level: RYTM has more cash than its total debt.
Reducing Debt: RYTM's debt to equity ratio has increased from 0% to 82.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RYTM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RYTM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/24 19:08 |
| End of Day Share Price | 2025/09/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rhythm Pharmaceuticals, Inc. is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |
| Jonathan Wolleben | Citizens JMP Securities, LLC |